ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Xilio Therapeutics Inc

Xilio Therapeutics Inc (XLO)

1.48
0.823
(125.27%)
Closed February 13 4:00PM
1.3501
-0.1299
(-8.78%)
After Hours: 7:59PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
1.3501
Bid
1.35
Ask
1.36
Volume
168,152,666
1.21 Day's Range 1.70
0.5001 52 Week Range 1.93
Market Cap
Previous Close
0.657
Open
1.35
Last Trade Time
Financial Volume
$ 238,830,124
VWAP
1.4203
Average Volume (3m)
515,666
Shares Outstanding
43,958,074
Dividend Yield
-
PE Ratio
-0.84
Earnings Per Share (EPS)
-1.74
Revenue
-
Net Profit
-76.4M

About Xilio Therapeutics Inc

Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. Leveraging the GPS platform, they are building a pipeline of tumor-selective cytokine and checkpoint inhibitor immuno... Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. Leveraging the GPS platform, they are building a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. The goal is to overcome the limitations of current I-O therapies by developing products with an improved therapeutic index. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Xilio Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker XLO. The last closing price for Xilio Therapeutics was $0.66. Over the last year, Xilio Therapeutics shares have traded in a share price range of $ 0.5001 to $ 1.93.

Xilio Therapeutics currently has 43,958,074 shares outstanding. The market capitalization of Xilio Therapeutics is $28.88 million. Xilio Therapeutics has a price to earnings ratio (PE ratio) of -0.84.

XLO Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.6842102.7481603840.66591.640.63151571270.67714699CS
40.250122.73636363641.11.640.633359270.90165578CS
120.375738.55706075530.97441.640.635156661.04621813CS
260.480155.1839080460.871.640.633592471.04088593CS
520.6936105.6511805030.65651.930.50015472701.13814732CS
156-13.2399-90.74640164514.5914.860.492278051.3892922CS
260-13.6499-90.99933333331527.950.492183412.1467835CS

XLO - Frequently Asked Questions (FAQ)

What is the current Xilio Therapeutics share price?
The current share price of Xilio Therapeutics is $ 1.3501
How many Xilio Therapeutics shares are in issue?
Xilio Therapeutics has 43,958,074 shares in issue
What is the market cap of Xilio Therapeutics?
The market capitalisation of Xilio Therapeutics is USD 28.88M
What is the 1 year trading range for Xilio Therapeutics share price?
Xilio Therapeutics has traded in the range of $ 0.5001 to $ 1.93 during the past year
What is the PE ratio of Xilio Therapeutics?
The price to earnings ratio of Xilio Therapeutics is -0.84
What is the reporting currency for Xilio Therapeutics?
Xilio Therapeutics reports financial results in USD
What is the latest annual profit for Xilio Therapeutics?
The latest annual profit of Xilio Therapeutics is USD -76.4M
What is the registered address of Xilio Therapeutics?
The registered address for Xilio Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Xilio Therapeutics website address?
The website address for Xilio Therapeutics is xiliotx.com
Which industry sector does Xilio Therapeutics operate in?
Xilio Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
GSATGlobalstar Inc
$ 21.05
(5,162.50%)
1.58M
TIVCTivic Health Systems Inc
$ 0.696717
(196.48%)
509.57M
SHOTWSafety Shot Inc
$ 0.4537
(143.14%)
6.73k
MYNAMynaric AG
$ 0.6152
(132.50%)
77.77M
KDLYKindly MD Inc
$ 3.26
(129.32%)
219.17M
ALCEAlternus Clean Energy Inc
$ 0.058
(-74.34%)
3.36M
MSWMing Shing Group Holdings Ltd
$ 3.0267
(-46.43%)
1.25M
TTOOT2 Biosystems Inc
$ 0.0784
(-41.49%)
5.84M
ATOMAtomera Incorporated
$ 5.315
(-38.55%)
4.29M
OTLYOatly Group AB
$ 0.394
(-32.62%)
30.93M
TIVCTivic Health Systems Inc
$ 0.696717
(196.48%)
509.57M
CYNCYNGN Inc
$ 0.1491
(-8.53%)
325.57M
KDLYKindly MD Inc
$ 3.26
(129.32%)
219.17M
NXUNXU Inc
$ 0.41
(49.69%)
184.67M
ADTXAditxt Inc
$ 0.0897
(-5.78%)
181.67M

XLO Discussion

View Posts
Preciouslife1 Preciouslife1 3 hours ago
Biotechnology Financial Analyst positive
This collaboration marks a transformative moment for Xilio Therapeutics, significantly strengthening its financial position and validating its tumor-activated biologics platform. The deal's structure is particularly noteworthy: the $52 million upfront payment, including a $10 million equity stake, provides immediate capital injection, while the $2.1 billion in potential milestone payments creates substantial long-term value potential.

The equity investment component is especially significant as it demonstrates AbbVie's strong commitment and confidence in Xilio's technology. This strategic alignment with a major pharmaceutical player provides Xilio with not just financial resources but also access to AbbVie's extensive oncology development expertise and commercial infrastructure.

The focus on masked T-cell engagers represents a cutting-edge approach in immuno-oncology. Traditional immunotherapies often face challenges with systemic toxicity, limiting their therapeutic window. Xilio's tumor-selective activation technology addresses this critical limitation by concentrating therapeutic activity within the tumor microenvironment, potentially enabling higher dosing and better efficacy while minimizing side effects.

From a financial perspective, this deal transforms Xilio's risk profile. The substantial upfront payment strengthens their balance sheet, while the milestone structure provides multiple value-creation opportunities throughout the development process. The tiered royalty structure ensures long-term value capture if products reach commercialization.

The partnership structure allows Xilio to retain significant value in their platform while leveraging AbbVie's resources for development and commercialization. This hybrid approach optimizes the risk-reward profile for both companies and potentially accelerates the development timeline for novel cancer therapeutics.
👍️0
madras50 madras50 8 hours ago
This should have crossed $2 today.
👍️0
81vette 81vette 9 hours ago
Hello EZ,thanks for alert,good to hear from you old friend! Good skill bro!
👍️0
81vette 81vette 11 hours ago
Going to be biggest bear trap in history,or great short,30k Ava.every 15m@only 4%fee
I am betting on rare bear trap,news is astronomical value increase.
👍️0
Stockexpertpro Stockexpertpro 11 hours ago
$XLO 52 Million in Cash and over 2 Billion in Milestone payments with $ABBV https://www.stocktitan.net/news/XLO/abb-vie-and-xilio-therapeutics-announce-collaboration-and-option-x3e2lxgw8uc1.html
👍️0
81vette 81vette 11 hours ago
AbbVie paying,$52m,upfront payment,up to $2.1Billion royalties,up front payment alone is close to mkt cap,under value much
👍️0
81vette 81vette 12 hours ago
https://ih.advfn.com/stock-market/NASDAQ/xilio-therapeutics-XLO/stock-news/95418853/xilio-therapeutics-announces-multiple-masked-t-cel
👍 1
81vette 81vette 12 hours ago
https://ih.advfn.com/stock-market/NASDAQ/xilio-therapeutics-XLO/trades
👍 1
81vette 81vette 12 hours ago
If pattern continues,it’s time for vol surge and this could be best yet as they continue to increase
👍 1
81vette 81vette 13 hours ago
11:30 vol surge started,that’s the pattern unless it surges on hr and 1/2 hr(that’s a really strong ticker) ohh wow as I am typing it blasts up 1.66 wee haww
👍️ 1
Invest-in-America Invest-in-America 13 hours ago
XLO: And there she GOES, Capt. Timmy!!! (Maybe??? Hopefully??? STRANGER things HAVE transpired on Wall Street Lane, ya know!!)

👍️0
81vette 81vette 14 hours ago
Death hour now (10:30-11:30)I don’t expect move until after 11 maybe 11:15 should start vol surges every hr if it’s strong enough
👍️ 1
81vette 81vette 14 hours ago
ZERO BORROW now ,fee is only 9% so I expect that to go up around 400% once shares are in more demand
👍️0
81vette 81vette 15 hours ago
Only 1k shares to short remain,ZERO BORROW coming and kaboom
👍️0
81vette 81vette 15 hours ago
Resistance is $5 $10 $15 value potential is astronomical
👍️0
Preciouslife1 Preciouslife1 15 hours ago
https://ih.advfn.com/stock-market/NASDAQ/xilio-therapeutics-XLO/stock-news/95418850/abbvie-and-xilio-therapeutics-announce-collaborati
👍️ 1
81vette 81vette 15 hours ago
Thank you bro for letting me know,I would have missed it.this is the news we were waiting for! Instant 10Xs value
👍️0
makinezmoney makinezmoney 16 hours ago
$XLO: Now 1.40 !

Good Call.......... keep em coming



GO $XLO
👍️0
TIMGZ TIMGZ 16 hours ago
$16 feasible. we shall see
👍️0
Invest-in-America Invest-in-America 16 hours ago
XLO: One of their PR's boasted, a "POTENTIAL 2-BILLION" income for them.
👍️0
tw0122 tw0122 17 hours ago
$1.43 ....Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers ....
👍️ 1
tw0122 tw0122 17 hours ago
Nice move $1.38 + 110%
👍️ 1
81vette 81vette 1 week ago
Running up at close is good,loaded up on chart reversal this morning
👍️0
Preciouslife1 Preciouslife1 3 weeks ago
January 21, 2025 at 5:05 PM EST
PDF Version27% preliminary response rate observed in heavily pre-treated microsatellite stable colorectal cancer (MSS CRC) patients without liver metastasesResponses were accompanied by decreases in levels of carcinoembryonic antigen (CEA) and circulating tumor DNA (ctDNA) and improvement in clinical symptomsData continue to demonstrate differentiated safety and tolerability profile for the combination with low incidence of immune-related adverse eventsXilio Therapeutics to host investor conference call and webcast on Wednesday, January 22, 2025, at 8:30 am ETWALTHAM, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced initial data from its ongoing Phase 2 clinical trial evaluating vilastobart (XTX101), a tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4, in combination with atezolizumab (Tecentriq®) in patients with metastatic microsatellite stable colorectal cancer (MSS CRC). The data will be presented in a poster session (abstract #206) at the American Society of Clinical Oncology 2025 Gastrointestinal Cancer Symposium (ASCO GI) being held January 23-25, 2025, in San Francisco.“We are very encouraged by the initial Phase 2 proof-of-concept data for the combination of vilastobart and atezolizumab in heavily pre-treated patients with MSS colorectal cancer, including partial responses accompanied by marked decreases in tumor biomarkers and improvement in clinical symptoms,” said Katarina Luptakova, M.D., chief medical officer of Xilio. “We believe these data highlight the important contribution of vilastobart in this combination, as PD-(L)1 inhibitors alone have demonstrated no meaningful efficacy in patients with MSS CRC to date. The preliminary evidence of anti-tumor activity, together with continued evidence of a well-tolerated safety profile, support the potential for the combination in MSS colorectal cancer, as well as in other tumors that have traditionally been resistant to treatment with immunotherapy. We look forward to sharing additional Phase 2 data, including further follow-up, in patients with metastatic MSS CRC in the middle of this year.”“These preliminary Phase 2 data for the combination of vilastobart and atezolizumab show clear responses for patients with MSS colorectal cancer, an area of very high and increasing unmet medical need,” said J. Randolph Hecht, M.D., Professor of Clinical Medicine at the David Geffen School of Medicine at UCLA, Director of the UCLA Gastrointestinal Oncology Program and the lead author for the presentation at ASCO GI. “I am excited to see these initial data highlighting the potential for vilastobart, a tumor-activated anti-CTLA-4, in combination with PD-(L)1 inhibitors to have clinically meaningful benefit in a classically immunotherapy-resistant major malignancy.”Data from Phase 2 Trial for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic MSS CRCAs of a data cutoff date of January 13, 2025, 40 patients with metastatic MSS CRC had been treated with the combination of vilastobart at a dose of 100 mg once every six weeks (Q6W) and atezolizumab at 1200 mg once every three weeks (Q3W). The median age was 55 years (ranging from 25 to 82 years), and patients were heavily pre-treated, with 70% of patients having previously received three or more prior lines of anti-cancer therapy.Preliminary Anti-Tumor Activity DataIn patients without liver metastases, the preliminary objective response rate (ORR) was 27% with three partial responses (PRs), including two confirmed PRs. Responses were accompanied by decreases in levels of carcinoembryonic antigen (CEA) and circulating tumor DNA (ctDNA) as well as improvement in clinical symptoms.As of the data cutoff date, 18 patients had at least one imaging scan reported and were evaluable for response assessment (per RECIST version 1.1 criteria), including 11 patients without liver metastases and seven patients with liver metastases.In response-evaluable MSS CRC patients without liver metastases, investigators reported three PRs (two confirmed, one pending confirmation), with each patient ongoing on treatment as of the data cutoff date:PR (confirmed) with a 47% decrease in the sum of diameters of target lesions at 13 weeks accompanied by a decrease in levels of the serum tumor marker CEA, a multi-log fold decrease in levels of ctDNA and improvement of clinical symptoms, such as cough. CEA is a serum biomarker that is often elevated in many malignancies, including colorectal cancer, and ctDNA is a biomarker found in the bloodstream of patients with cancer.

PR (confirmed) that continued to deepen over time with a 57% reduction in the sum of diameters of target lesions at 18 weeks accompanied by a multi-log fold decrease in ctDNA to undetectable levels and significant decrease in levels of the serum tumor marker CEA to normal values.

PR (pending confirmation) with a 35% decrease in the sum of diameters of target lesions at nine weeks accompanied by a decrease in levels of the tumor marker CEA to normal values, a substantial decrease in levels of ctDNA and improvement of clinical symptoms, such as cough. For this patient, the initial response on CT imaging was assessed by the investigator and the radiology assessment is pending.
In addition, an MSS CRC patient without liver metastases but with a peritoneal metastasis had a 24% decrease in the sum of diameters of target lesions assessed by CT imaging at their initial nine-week scan accompanied by a decrease in levels of the serum tumor marker CEA to normal values. This patient was ongoing on treatment as of the data cutoff date.Investigators reported stable disease in three patients without liver metastases and one patient with liver metastases, representing a preliminary disease control rate of 55% and 14%, respectively, and highlighting additional evidence of anti-tumor activity for the combination.As of the data cutoff date, 23 patients were ongoing on treatment, including 13 patients who had not yet had a first response assessment.Preliminary Safety DataSafety data continue to support the potential for vilastobart to be a differentiated next-generation anti-CTLA-4 in combination with PD-(L)1 inhibitors. Consistent with the tumor-selective design for vilastobart, the combination was generally well-tolerated, with patients experiencing a low incidence of immune-related adverse events (irAEs) and only 5% of patients reporting colitis.As of the data cutoff date, 40 patients were evaluable for safety. Across all patients treated:Investigators reported only six patients with Grade 3 or 4 treatment-related adverse events (AEs), including only two Grade 4 treatment-related AEs (laboratory abnormalities of thrombocytopenia and neutropenia, one patient each), and no Grade 5 treatment-related AEs.No patients experienced a dose reduction for vilastobart due to an AE, and only three patients discontinued treatment for the combination of vilastobart and atezolizumab due to a treatment-related AE.Investigators reported minimal endocrine irAEs (5%) and limited skin irAEs (13%), and the incidence of endocrine and skin irAEs was consistent with the incidence reported for atezolizumab alone.The most common treatment-related AEs (≥10% incidence) of any grade reported by investigators were the following: fatigue (30%); diarrhea (20%); infusion-related reactions (13%, with 8% deemed related to vilastobart and 5% deemed related to atezolizumab); pyrexia (10%); aspartate aminotransferase (AST) increase (10%); and alanine aminotransferase (ALT) increase (10%).The only Grade 3 treatment-related AE with ≥5% incidence reported by investigators was colitis (5%). Non-laboratory Grade 3 treatment-related AEs (<5% incidence) consisted of the following: maculopapular rash and febrile neutropenia in one patient; lower gastrointestinal hemorrhage in one patient with thrombocytopenia; and one patient with Triple M overlap syndrome (myocarditis, myositis and myasthenia gravis).
Clinical Development Plans for VilastobartThe Phase 2 clinical trial evaluating vilastobart in combination with atezolizumab in patients with MSS CRC is currently ongoing, and Xilio expects to report updated data from the Phase 2 trial in the middle of 2025, including additional response assessments and follow-up.These initial Phase 2 proof-of-concept data demonstrate the potential for vilastobart as a combination therapy in patients with MSS CRC and a range of other tumor types, including “cold” tumors historically resistant to immunotherapy. Based on these data, Xilio plans to seek opportunities for partnering to prioritize and expand further development beyond the initial Phase 2 proof-of-concept trial in MSS CRC.In addition, Xilio continues to enroll patients in Phase 1C dose escalation and evaluate the combination of vilastobart at the 150 mg Q6W dose level and atezolizumab at 1200 mg Q3W.Investor Conference Call Information
Xilio will host a conference call and webcast tomorrow (Wednesday, January 22, 2025) at 8:30 am ET to discuss the initial Phase 2 data for the combination of vilastobart and atezolizumab. Viewers can access the webcast by using this link. Listeners who require dial-in access should register here to receive a unique PIN and information to join the call. Listeners are encouraged to join at least 15 minutes prior to the scheduled start time. The webcast will also be accessible under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at https://ir.xiliotx.com. A replay of the webcast will be archived on the website for 30 days following the presentation.About Vilastobart (XTX101) and the Phase 1/2 Combination Clinical TrialVilastobart is an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody designed to block CTLA-4 and deplete regulatory T cells when activated in the tumor microenvironment (TME). In 2023, Xilio entered into a co-funded clinical trial collaboration with Roche to evaluate vilastobart in combination with atezolizumab (Tecentriq®) in a multi-center, open-label Phase 1/2 clinical trial. Xilio is currently evaluating the safety of the combination in Phase 1C dose escalation in patients with advanced solid tumors and the safety and efficacy of the combination in Phase 2 in patients with metastatic microsatellite stable colorectal cancer with and without liver metastases. Please refer to NCT04896697 on www.clinicaltrials.gov for additional details.
👍️ 1
Preciouslife1 Preciouslife1 3 weeks ago
https://ir.xiliotx.com/news-releases/news-release-details/xilio-therapeutics-announces-initial-phase-2-data-vilastobart
👍️ 1
Preciouslife1 Preciouslife1 4 weeks ago
https://ir.xiliotx.com/news-releases/news-release-details/xilio-therapeutics-announces-inducement-grant-under-nasdaq-0
👍️0
tbonaces80 tbonaces80 2 months ago

Here it is
👍️0
tbonaces80 tbonaces80 2 months ago
Bullish pennant on continuation. Thank me later
👍️ 2
tbonaces80 tbonaces80 2 months ago
Strike is easily $1.97. News or approval and we go hard
👍️0
tbonaces80 tbonaces80 2 months ago
Loaded a nice position here
👍️0
Preciouslife1 Preciouslife1 2 months ago
https://ir.xiliotx.com/news-releases/news-release-details/xilio-therapeutics-present-initial-phase-2-data-vilastobart
👍 1
PonkenPlonken PonkenPlonken 2 months ago
trades below cash value
Makes no f in sense!
stick it out......
👍️ 1
Preciouslife1 Preciouslife1 3 months ago
https://ir.xiliotx.com/news-releases/news-release-details/xilio-therapeutics-announces-initial-clinical-trial-data-phase
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
XLO HERE WE GO
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
BIO BEAST
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
XLO MONSTER BREAK
👍 1
TrendTrade2016 TrendTrade2016 3 months ago
XLO BUILDING STEAM
👍 1
PonkenPlonken PonkenPlonken 3 months ago
running towards two readouts with Gilead sitting at 17% ownership at 1.97$ strike. I have the hubris to say this WILL GO GO
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
XLO HERE WE GO
👍️0
PonkenPlonken PonkenPlonken 3 months ago
COMING TO LIFE
masked antibodies
👍 1
TrendTrade2016 TrendTrade2016 3 months ago
XLO...MINI BIO BEAST
👍 1
Laster Laster 3 months ago
Got some at $1.00 several days ago.
I like the share structure. It might run for a few days.
Looking for $1.40 if I am lucky.
👍️ 1
Preciouslife1 Preciouslife1 4 months ago
https://ir.xiliotx.com/news-and-events/news-releases
👍️ 1
Preciouslife1 Preciouslife1 4 months ago
https://www.linkedin.com/posts/hashem-al-ghaili-1b30679b_drug-resistant-bacteria-are-projected-to-activity-7246464071565201410-sAL9?utm_source=share&utm_medium=member_ios
👍️0
Preciouslife1 Preciouslife1 5 months ago
This information makes one wonder IF BRILICIDIN IS BEING SUPPRESSED TOO: https://www.facebook.com/share/r/MTAzjcdR5iGnab4t/?mibextid=6GsUZ4
👍️ 1
Preciouslife1 Preciouslife1 6 months ago
https://www.gilead.com/news-and-press/press-room/press-releases/2024/3/gilead-and-xilio-announce-exclusive-license-agreement-for-tumor-activated-il-12-program
👍️0
PonkenPlonken PonkenPlonken 6 months ago
Gilead paid 13.5mn$ @ 1.97
The results of their partnered program and another one will be reported in Q4 24
masked antibodies... very little toxicity.
I have a small position... Think big rally coming into 2025- atleast to the 1.97 strike.


"Under the License Agreement, the Company will receive approximately $43.5 million in upfront payments, including a cash payment of $30.0 million and an initial equity investment by Gilead of approximately $13.5 million in the Company’s common stock, $0.0001 par value per share (the “Common Stock”), at a purchase price of $1.97 per share. The Company will be eligible to receive up to $604.0 million in additional contingent payments, which include (i) the proceeds from up to three additional private placements of Common Stock, (ii) the $75.0 million transition fee and (iii) specified development, regulatory and sales-based milestones. Prior to the potential transition fee, up to $29.0 million of the total contingent payments are related to the potential additional private placements of Common Stock and a near-term development milestone. In addition, the Company is eligible to receive tiered royalties ranging from high single digits to mid-teens on annual global net product sales."

"In addition, through March 27, 2025, the Company may, at its election and subject to the terms and conditions of the Stock Purchase Agreement, cause Gilead to purchase up to approximately $11.5 million of additional shares of Common Stock (including, at Gilead’s sole election, prefunded warrants in lieu of shares of Common Stock) in up to three additional private placements (each, an “Additional Gilead Private Placement”) at a predetermined price per share..."
👍️ 1
PonkenPlonken PonkenPlonken 8 months ago
XLO -- unique masking approach and great results. Hot field $JANX. Gilead certainly thinks so - buys real equity. Company trades below the upfront payment...

https://schrts.co/tdtYZDEX
👍️0
Preciouslife1 Preciouslife1 8 months ago
Hi I tried to buy a bunch of shares this morning once at .885 then at .90; never filled though over the ASK PRICE then it took off upwards! MM MANIPULATION MUCH!?!?
👍️0
Laster Laster 9 months ago
Stock closed the gap. They are in the right biotech area similar to CLRB and CTMX and SNSE.
Only a matter of time before this explodes to $2 or higher.
JMO.
👍️0

Your Recent History

Delayed Upgrade Clock